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Introduction {#sec001}
============

Regular physical activity (PA) and physical fitness (PF) are closely related to a positive health status in humans \[[@pone.0189254.ref001], [@pone.0189254.ref002]\]. In contrast, being inactive increases the risk of developing chronical disease \[[@pone.0189254.ref003], [@pone.0189254.ref004]\]. Several mechanisms are involved in the health inducing effect of exercise \[[@pone.0189254.ref005]\]. In this context, the muscle seems to play an important role as a secretory organ \[[@pone.0189254.ref006]\]. The substances that are supposed to be secreted by the muscles are named "myokines" \[[@pone.0189254.ref007]\]. Myokines seem to be secreted by the muscle in response to PA \[[@pone.0189254.ref008]\] and they are assumed to be involved in PA induced positive health effects \[[@pone.0189254.ref009]\] by generating their effects in an auto-, para-, or endocrine manner \[[@pone.0189254.ref010]\].

Within the last few years, rising attention has been given to the myokine Irisin. Its secretion into the circulation occurs after transcription from its fibronectin type III domain containing protein 5 gene and proteolytical cleavage at the extracellular surface of cells \[[@pone.0189254.ref011]\]. Fibronectin type III domain containing protein 5 gene expression mainly takes place in muscle tissue and to a lesser degree in other tissues, such as adipose tissue \[[@pone.0189254.ref012]\]. Its secretion thought to be triggered by the peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1 alpha (PGC-1 alpha), whose expression in turn is induced by PA \[[@pone.0189254.ref013]--[@pone.0189254.ref015]\]. It is speculated that Irisin induces browning of white adipose tissue. Browning describes the development of multilocular, uncoupling protein 1 positive adipocyte inside fat tissue, which is supposed to have a beneficial impact on energy expenditure and whole body homeostasis \[[@pone.0189254.ref011], [@pone.0189254.ref016]--[@pone.0189254.ref018]\]. Due to the postulated browning inducing effect, Irisin might be an important target for reducing the risk of developing overweight associated diseases \[[@pone.0189254.ref019]\]. It is therefore a major target in current research to identify Irisin as a mediator of the PA inducing health effects.

Results from current studies focusing on the influence of PA on circulating Irisin are inconsistent. While most studies show an impact of acute PA on Irisin blood concentrations \[[@pone.0189254.ref020]--[@pone.0189254.ref029]\], results on the association between PA status \[[@pone.0189254.ref020], [@pone.0189254.ref030]\], and PF \[[@pone.0189254.ref025], [@pone.0189254.ref026], [@pone.0189254.ref031], [@pone.0189254.ref032]\] on resting Irisin concentrations are inhomogeneous. Additionally, results of intervention studies investigating a given workload or time of intervention on circulating Irisin are also inconsistent \[[@pone.0189254.ref022], [@pone.0189254.ref024], [@pone.0189254.ref026], [@pone.0189254.ref030], [@pone.0189254.ref032]--[@pone.0189254.ref036]\].

The inhomogeneity of the results of current data might be related to differences in study characteristics, e.g. study designs and number and type of tests of determining PA and Irisin concentration. Speculating that myokines at least partly mediate exercise related health effects one would assume that regular PA and PF are associated with resting Irisin concentrations in healthy humans.

Therefore, the aim of this study was to obtain a comprehensive overview of the PA status by determining different markers of short-term and habitual PA as well as PF in a well described cohort of healthy humans under strictly controlled conditions and thereby investigating the association between resting Irisin concentrations in serum and PA status and PF.

Material and methods {#sec002}
====================

Participant characteristics and study design {#sec003}
--------------------------------------------

For the present analysis, data from the cross-sectional Karlsruhe Metabolomics and Nutrition (KarMeN)-study were used \[[@pone.0189254.ref037]\]. The study was conducted between March 2012 and July 2013 at the Human Studies Division of the Max Rubner-Institut in Karlsruhe, Germany. The aim of KarMeN was to investigate the associations of the metabolome with major lifestyle factors, like nutrition and PA and the health status of healthy man and women of different ages. After the recruitement process a total of 301 healthy male and female participants aged 18--80 years remained. Health status was assessed by collecting medical history data and conducting basic physical examination. Volunteers suffering from acute or chronic therapy requiring diseases were excluded. Details on inclusion and exclusion criteria and detailed information on the study design are published elsewhere \[[@pone.0189254.ref037]\]. Briefly, all of the participants were required to visit the study center for a total of three times and underwent a series of examinations, e.g. fasting blood sampling, indirect calorimetry, and cardiopulmonary exercise testing. Each examination day followed an identical schedule and the examinations were conducted following standard operating procedures. For our research we had to exclude one subject because of missing myokine data. Therefore data of 300 healthy participants served to investigate the association between fasting serum Irisin concentrations and short-term, habitual PA, and PF.

Ethics and dissemination {#sec004}
------------------------

The study has been performed in accordance with the Declaration of Helsinki. It was registered at the German Clinical Trials Register (No: DRKS00004890) and approved by the Ethics Committee of the State Medical Chamber of Baden-Württemberg, Stuttgart, Germany (F- 2011- 051). Approval for dual-energy X-ray absorptiometry (DXA) measurements in healthy participants was obtained from the Federal Office for Radiation Protection (Z5- 22462/2-2011-043). All participants were informed in detail about the examinations, procedures, and measurements and gave their written consent. Confidentiality of personal data was guaranteed by following the regulations of the State Medical Chamber and the Federal Data Protection Act.

Sample processing, storage, and Irisin analysis {#sec005}
-----------------------------------------------

For Irisin and insulin analysis fasting serum samples were collected. After collection, the samples were immediately centrifuged (1850g by 4C°), aliquoted into cryo vials, and stored in the gas phase of liquid nitrogen (below -190°C). To determine the coefficient of variability, an internal quality control sample was prepared from pooled serum samples. The coefficient of variability served to express the repeatability and precision of the test. Blood samplings were placed around the activity measurements, to combine relevant parameters for metabolic biostatistical analysis. See the study design for more details published elsewhere \[[@pone.0189254.ref037]\]. Irisin and insulin serum concentrations were determined by Enzyme-linked Immunosorbent Assays (ELISA) (Irisin: EK-067-29 from Phoenix Pharmaceuticals, Karlsruhe, Germany; Insulin: ME E-0900 from LDN, Nordhorn,Germany). All analyses were implemented according to the manufacturer's instructions. For Glucose and HbA1c, blood were analyzed by a certified clinical chemistry laboratory (MZV Labor PD Dr Volkmann, Karlsruhe, Germany).

Anthropometry {#sec006}
-------------

Body height (in cm) and body weight (in kg) was measured in underwear and without shoes using a standardized scale and stadiometer from Seca (Seca 285, Hamburg, Germany). Body mass index (BMI) was calculated by dividing the weight (kg) by square of height in metres (m^2^).

Body composition was measured using the GE Lunar iDXA (GE Healthcare, Munich, Germany). To ensure minimal x-ray absorption by clothing or other objects, participants were asked to lie on the scanner table only wearing underwear. Participants positioned themselves on the table according to the instructions of the study nurse. Lean body mass (LBM) and fat mass (FM) were calculated with the supplementary software Body Composition. FM in percent was described as percentage of the total body weight estimated by DXA.

Resting energy expenditure {#sec007}
--------------------------

Resting energy expenditure (REE) was analyzed by indirect calorimetry using Vmax™ Encore indirect calorimeter (Vmax-Serie 29n, CareFusion Germany 234 GmbH, Hoechberg, Germany). The measurements were performed according to the manufacturer\'s instructions. The oxygen uptake and carbon dioxide exhalation were measured with a canopy while the participants were lying in a quiet, thermo-neutral room. All measurements were performed in fasting condition (from 10 p.m. the day before). REE was calculated by the Vmax™ Encore software (version v21-2A) and is indicated in kcal per 24 hours.

Physical activity and fitness assessment {#sec008}
----------------------------------------

To cover aspects of PA as well as PF, we applied three different activity assessment tools each for a specific time period and categorized the outcome parameters into three groups: short-term PA, habitual PA and PF ([Table 1](#pone.0189254.t001){ref-type="table"}).

10.1371/journal.pone.0189254.t001

###### Physcial activity categories and the corresponding examinations and outcome parameters.

![](pone.0189254.t001){#pone.0189254.t001g}

  Categories                                             Examinations                                    Outcome parameters   Outcome parameters representing PA categories   
  ------------------------------------------------------ ----------------------------------------------- -------------------- ----------------------------------------------- -----
  Short-term physical activity                           Accelerometry                                   AEE                  AEE                                             TEE
  Indirect calorimetry                                   REE                                                                                                                  
  Thermogenesis [^a^](#t001fn002){ref-type="table-fn"}   DIT                                                                                                                  
  TEE / REE                                                                                              PAL                                                                  
  Habitual physical activity                             International Physical Activity Questionnaire                        MET                                             
  Physical fitness                                       Cardiopulmonary exercise test                                        VO~2\ peak~                                     
  Cardiopulmonary exercise test and lactate test                                                         P~IAT~                                                               

AEE, activity energy expenditure; REE, resting energy expenditure; DIT, diet-induced thermogenesis; TEE, total energy expenditure; PAL, physical activity level; MET, metabolic equivalent of task; VO~2\ peak~, peak oxygen consumption; P~IAT~, power at individual anaerobic threshold.

^a^ 10% of TEE for diet-induced thermogenesis

Short-term physcial activity {#sec009}
----------------------------

The level of short-term PA was analyzed over a period of seven consecutive days using Actiheart^®^ (CamNtech, Cambridge, UK), a device that combines heart rate monitoring and an uniaxial accelerometer to assess movement. Actiheart^®^ is waterproof and weighs 10 g. Participants were instructed to wear Actiheart^®^ during all activities day and night (with the exception of visiting the sauna or solarium and while diving). The device was attached with electrodes (Red Dot™ EKG Elektrode 2271, 3M™, Neuss, Germany) on the left lower chest. In this study Actiheart^®^ was set up to record heart rate and movement counts with a time interval of 15 s. Data from Actiheart^®^ devices were downloaded after measurement and analyzed using the supplied software (version 4.0.103, CamNtech, Cambridge, UK). This provided estimates of the activity energy expenditure (AEE) in kcal per day. The mean total energy expenditure (TEE) in kcal per day was calculated with AEE measured by Actiheart^®^, REE measured by indirect calorimetry, and diet-induced thermogenesis (assuming 10% of TEE). Physical activity level (PAL) was calculated by dividing calculated TEE by measured REE.

Habitual physical activity {#sec010}
--------------------------

To determine the habitual PA of the last three months, the participants were asked to fill out the international physical activity questionnaire (IPAQ). We applied the long-form of the IPAQ that covers frequency and duration of each activity, such as walking, moderate and vigorous activities in each of the following domains: work, active transportation, leisure-time, domestic, and garden. Only sustained activities of more than 10 minutes should be noted. In accordance with the guidelines published on the IPAQ website \[[@pone.0189254.ref038]\], the mean PA per week was calculated and is expressed in metabolic equivalent of task (MET)-minutes per week.

Physical fitness {#sec011}
----------------

As a measure of PF, aerobic endurance capacity was assessed by conducting a standard exercise test on a bicycle ergometer (Ergobike medical, Daum, Fürth, Germany). The test was implemented according to the WHO-loading protocol \[[@pone.0189254.ref039]\], starting at 25 Watt with an increment of 25 Watt every 2 minutes until individual exhaustion. During the test highest achieved oxygen consumption (VO~2\ peak~) was assessed by using a cardiopulmonary exercise testing system (MetaMax 3 B, Cortex, Leipzig/Germany). Power at individual anaerobic threshold (P~IAT~) was determined by additional implementation of a lactate test (Biosen C-Line, EKF, Barleben, Germany). Therefore, capillary blood samples were taken from the participant's earlobe immediately before the test, at the end of every workload level, at the end of the test, and after 1, 3, and 5 minutes of recovery. Determination of P~IAT~ (lactate treshold + 1,0 mmol/l for cycling \[[@pone.0189254.ref040]\]) was carried out via Ergonizer software (Ergonizer, Version 4, Freiburg, Germany). Prior to the study, break-off criteria were defined and if one of these was reached the test was stopped. The break-off criteria were defined by the study doctor according to national standards for ergometry and recorded in the SOP. Break-off criteria were e.g. ST-segment depression \>3mm; ST-segment elevation\>1mm, acute hypertension (RR syst. \>230mmHG, RR diast \>115mmHg), appearance of angina pectoris symptoms or severe dyspnea. For this purpose, we measured the heart rate during the test period by using a heart rate monitor (T31 coded, Polar Electro GmbH Deutschland, Büttelborn, Germany). Throughout the entire procedure hemodynamic monitoring was conducted by running a 12-channel elektrocardiogram (CardioDirect 12, DelMar Reynolds GmbH, Feucht, Germany) and measuring the blood pressure every 2--3 minutes on the right upper arm by using a blood pressure monitor (boso Carat professional, Bosch + Sohn, Jungingen, Germany).

Statistical methods {#sec012}
-------------------

For the entire statistical analysis the statistic software SAS JMP 11.0.0 (SAS Institute Inc. 2013, Cary, NC, USA) was used. Data that fell within the normal distribution are shown as mean ± standard deviation (SD). Data that were not normally distributed are shown as median and interquartile range (IQR). For further statistical analysis, variables that were not normaly distributed were log-transformed. For Irisin Box-Cox-Transformation was used. Students t-test was generally used to investigate sex differences for all normally distributed parameters. If data were still not normally distributed after log-transformation, the Wilcoxon test was used. In case variance homogeneity was not given, the Welch correction factor for students t-test or median test instead of Wilcoxon were used. Since body composition and different PA parameters differ enormously between sexes, we also stratified our study group according to sex for further statistical analysis to eliminate the strongest confounder from the very beginning. We used a multivariate linear regression model (MLRA) to investigate associations of the individual PA parameters with Irisin concentrations. Irisin appears to be related to age, FM, LBM and parameters of glucose metabolism in the literature. Therefore, we additionally adjusted the models for these confounders to find the independent influence of PA on the resting Irisin concentration. In order to fulfill the criteria for the MLRA we performed box-cox-transformation of the models and ran outlier diagnostics. The outliers were identified by visual inspection of the predicted versus the studentized residuals plots. Studentized residuals outside the range of -3 and 3 were excluded from future analysis. These plots were also used to ensure homoscedasticity. In total we calculated 12 models for the dependent variable Irisin, 6 for each sex. For each model we focused on one of the 6 PA parameters AEE (kcal/d), TEE (kcal/d), PAL, Total MET (MET- min/week), VO~2\ peak~ (l/min), and P~IAT~ (watt) that was adjusted in each case to age (years), FM (%), LBM (g), Glucose (mg/dl), HbA1c (mmol/mol) and Insulin (μlU/ml). In order to evaluate the results, we focused on R^2^ and the significance of the individual models. The latter was calculated by using the F-Test. P-values of the models below 0.05 were considered as statistically significant. The participant numbers for the physical parameters differ due to missing data and because outliers were excluded for further MLRA statistical analysis.

Results {#sec013}
=======

Characteristics and sex differences {#sec014}
-----------------------------------

[Table 2](#pone.0189254.t002){ref-type="table"} shows the characteristics of 172 men and 128 women participating in the KarMeN study. All participants were non-smokers. Male participants were between 20 and 80 years of age and female participants were 19 to 80 years of age. Statistically significant sex differences were observed for age, body weight, BMI, FM (kg, %), LBM (kg, %), AEE, TEE, VO~2\ peak~, P~IAT~ and HbA1c. Men were younger than women and had significantly higher levels of LBM (kg, %), AEE, TEE, VO~2\ peak~, and P~IAT~.

10.1371/journal.pone.0189254.t002

###### Characteristics of study participants separated by sex.
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                                                                                                        Men   Women                                                                                
  ----------------------------------------------------------------------------------------------------- ----- ------- ------ ----- ------- ------ ------------------------------------------------ -------
  Age (years)[\*^2^](#t002fn003){ref-type="table-fn"}                                                   172   44.1    35.5   128   54.0    21.5   0.0002[^†^](#t002fn007){ref-type="table-fn"}     
  Body weight (kg)[\*^1^](#t002fn002){ref-type="table-fn"}                                              172   79.2    10.2   128   63.5    11.5   \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  BMI (kg/m^2^)[\*^2^](#t002fn003){ref-type="table-fn"}                                                 172   24.0    4.3    128   22.7    4.0    \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  FM (kg)[\*^2^](#t002fn003){ref-type="table-fn"}                                                       172   18.0    10.6   128   21.2    8.4    \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  FM (%)[\*^2^](#t002fn003){ref-type="table-fn"}[\*^3^](#t002fn004){ref-type="table-fn"}                172   23.6    10.1   128   33.4    6.6    \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  LBM (kg)[\*^1^](#t002fn002){ref-type="table-fn"}                                                      172   58.0    6.6    128   40.3    3.8    \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  LBM (%)[\*^2^](#t002fn003){ref-type="table-fn"}[\*^3^](#t002fn004){ref-type="table-fn"}               172   72.5    9.2    128   63.0    6.3    \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  AEE (kcal/d)[\*^2^](#t002fn003){ref-type="table-fn"}                                                  169   969     675    127   702     332    \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  TEE (kcal/d)[\*^2^](#t002fn003){ref-type="table-fn"}                                                  169   2827    1023   127   2107    451    \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  PAL[\*^2^](#t002fn003){ref-type="table-fn"}                                                           169   1.81    0.47   127   1.80    0.31   0.558                                            0.120
  Total MET(MET-min/week)[\*^2^](#t002fn003){ref-type="table-fn"}                                       172   4205    4012   128   5169    5213   0.168                                            0.720
  VO~2\ peak~ (l/min)[\*^1^](#t002fn002){ref-type="table-fn"}[\*^4^](#t002fn005){ref-type="table-fn"}   166   3.37    0.85   114   1.89    0.54   \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  P~IAT~ (watt)[\*^1^](#t002fn002){ref-type="table-fn"}                                                 164   169.1   41.0   119   107.5   22.1   \<0.0001[^†^](#t002fn007){ref-type="table-fn"}   
  Glucose (mg/dl)[\*^2^](#t002fn003){ref-type="table-fn"}                                               172   86.0    10.0   128   85.0    8.0    0.120                                            0.744
  HbA1c (mmol/mol)[\*^2^](#t002fn003){ref-type="table-fn"}                                              172   34.4    5.5    128   35.5    5.5    0.019[^†^](#t002fn007){ref-type="table-fn"}      
  Insulin (μlU/ml)[\*^2^](#t002fn003){ref-type="table-fn"}                                              172   9.3     4.8    128   9.0     5.3    0.210                                            0.188
  Irisin (ng/ml)[\*^2^](#t002fn003){ref-type="table-fn"}                                                172   9.9     1.8    128   10.2    1.7    0.085                                            0.592

AEE, activity energy expenditure; BMI, body mass index; FM, fat mass; LBM, lean body mass; MET, metabolic equivalent; PAL, physical activity level; P~IAT~, power at individual anaerobic threshold; TEE, total energy expenditure; VO~2\ peak~, peak oxygen consumption; P, Post-Hoc-Analysis for non significant sex differences

\*^1^ mean ± SD

\*^2^ median ± IQR

\*^3^mean ± SD for women

\*4 median ± IQR for women

^a^ Difference between men and women

^†^ significant at p \< 0.05

Association between Irisin and physical activity or fitness parameters {#sec015}
----------------------------------------------------------------------

[Table 3](#pone.0189254.t003){ref-type="table"} shows the results of the MLRA for Irisin stratified for men and women. Regression analysis revealed that non of the models were associated with resting Irisin concentrations, neither in men, nor in women. For Irisin the R^2^ was between 0.013 (for P~IAT~ in men) and 0.072 (for AEE in women).

10.1371/journal.pone.0189254.t003

###### Multivariate linear regression analysis for Irisin separated by sex.
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                             Men   Women                                                           
  -------------------------- ----- ------- ------- -------- ------- ----- ------- ------- -------- -------
  Model AEE                  166   0.049   0.327            0.520   125   0.072   0.253            0.578
  AEE (kcal/d)                             0.030   -0.223                         0.088   0.166     
  Age (years)                              0.665   -0.053                         0.277   0.131     
  FM (%)                                   0.715   -0.035                         0.429   -0.085    
  LBM (g)                                  0.175   0.119                          0.409   0.081     
  Glucose (mg/dl)                          0.254   -0.113                         0.210   -0.137    
  HbA1c (mmol/mol)                         0.487   0.069                          0.382   0.093     
  Insulin (μlU/ml)                         0.304   -0.089                         0.066   0.185     
  Model TEE                  166   0.042   0.449            0.441   126   0.068   0.290            0.549
  TEE (kcal/d)                             0.061   -0.211                         0.030   0.237     
  Age (years)                              0.698   -0.049                         0.340   0.114     
  FM (%)                                   0.770   -0.028                         0.549   -0.064    
  LBM (g)                                  0.137   0.142                          0.942   0.008     
  Glucose (mg/dl)                          0.304   -0.102                         0.360   -0.099    
  HbA1c (mmol/mol)                         0.556   0.058                          0.453   0.080     
  Insulin (μlU/ml)                         0.324   -0.085                         0.251   0.114     
  Model PAL                  166   0.047   0.353            0.502   126   0.035   0.743            0.278
  PAL                                      0.035   -0.201                         0.426   0.075     
  Age (years)                              0.749   -0.038                         0.554   0.071     
  FM (%)                                   0.704   -0.037                         0.785   -0.029    
  LBM (g)                                  0.310   0.085                          0.217   0.119     
  Glucose (mg/dl)                          0.211   -0.125                         0.404   -0.092    
  HbA1c (mmol/mol)                         0.455   0.074                          0.445   0.083     
  Insulin (μlU/ml)                         0.320   -0.086                         0.241   0.118     
  Model Total MET            169   0.018   0.891            0.191   128   0.030   0.810            0.240
  Total MET (MET-min/week)                 0.890   0.011                          0.380   -0.093    
  Age (years)                              0.741   0.038                          0.773   0.036     
  FM (%)                                   0.721   -0.035                         0.904   -0.013    
  LBM (g)                                  0.579   0.046                          0.195   0.124     
  Glucose (mg/dl)                          0.292   -0.106                         0.480   -0.078    
  HbA1c (mmol/mol)                         0.543   0.060                          0.305   0.114     
  Insulin (μlU/ml)                         0.584   -0.047                         0.503   0.067     
  Model VO~2\ peak~          164   0.015   0.935            0.159   114   0.032   0.834            0.226
  VO~2\ peak~ (l/min)                      0.663   -0.057                         0.346   0.145     
  Age (years)                              0.992   -0.001                         0.368   0.137     
  FM (%)                                   0.694   -0.041                         0.860   0.020     
  LBM (g)                                  0.626   0.048                          0.415   0.095     
  Glucose (mg/dl)                          0.538   -0.061                         0.595   -0.062    
  HbA1c (mmol/mol)                         0.734   0.034                          0.549   0.068     
  Insulin (μlU/ml)                         0.355   -0.080                         0.847   0.020     
  Model P~IAT~               161   0.013   0.958            0.139   119   0.021   0.931            0.162
  P~IAT~ (watt)                            0.553   -0.067                         0.867   0.021     
  Age (years)                              0.657   0.052                          0.988   -0.002    
  FM (%)                                   0.668   -0.045                         0.989   0.002     
  LBM (g)                                  0.420   0.083                          0.313   0.109     
  Glucose (mg/dl)                          0.382   -0.089                         0.492   -0.078    
  HbA1c (mmol/mol)                         0.710   0.038                          0.490   0.078     
  Insulin (μlU/ml)                         0.701   -0.034                         0.509   0.068     

AEE: activity energy expenditure; P~IAT~: power at individual anaerobic threshold; MET: metabolic equivalent; PAL: physical activity level; TEE: total energy expenditure; VO~2\ peak~: maximal oxygen consumption; FM: fat mass; LBM: lean body mass; P: Post-Hoc-Analysis

Discussion {#sec016}
==========

The current study served to investigate the association between resting Irisin concentrations and regular PA and PF status in serum of healthy humans. Our data show that none of the determined PA parameters comprising AEE, TEE, PAL, Total MET, VO~2\ peak~, and P~IAT~ are associated with resting Irisin serum concentration, suggesting that PA level and PF status are not related to resting Irisin concentrations in healthy humans.

Acute exercise increases Irisin blood concentration \[[@pone.0189254.ref020]--[@pone.0189254.ref029]\]. Data from the association between habitual PA \[[@pone.0189254.ref020], [@pone.0189254.ref030]\] or PF \[[@pone.0189254.ref025], [@pone.0189254.ref026], [@pone.0189254.ref031], [@pone.0189254.ref032]\] with resting Irisin concentrations are still inconsistent and additionally less well investigated.

In our study we applied three different activity assessments and categorized the outcome parameters into three different groups: short-term PA, habitual PA, and PF in order to obtain a comprehensive evaluation of the PA status and PF and finally to examine the relationship between these and the resting Irisin concentration in healthy humans. Furthermore, we calculated data separated by sex to eliminate the strongest confounder from the very beginning.

In line with our results other studies did not find a significant relationship between the resting Irisin concentration and PF in healthy subjects \[[@pone.0189254.ref026], [@pone.0189254.ref032]\], whereas Daskalopoulou and colleagues did not separate the study group according to sex in their statistical analysis. In contrast Kerstholt and colleagues found an inverse association between the Irisin concentration and the two PA parameters VO~2\ peak~ and Pmax in 322 men, whereas a significant positive association between VO~2\ peak~ could be found in a subgroup of 418 women, after excluding those whose time between VO~2\ peak~ determination and blood collection was too large \[[@pone.0189254.ref031]\]. We also separated our study group for statistical analysis and could not find any association between the resting Irisin concentration and VO~2\ peak~ in both sexes. Consistent with the results of Kerstholt and colleagues, others found a lower baseline Irisin concentration in physically active compared to sedentary male subjects \[[@pone.0189254.ref025]\]. Compared to Huh and colleagues, we used multivariate linear regression analysis instead of separating our study population in active and sedentary groups, to eliminate the bias of marginal groups.

Similar to our results Anastasilakis and colleagues also did not find a statistically significant difference between habitual PA levels and resting Irisin in healthy young subjects by using a modified version of the IPAQ and separating the study population into low, moderate, or high physical active groups \[[@pone.0189254.ref020]\]. In contrast, a weak association could be shown between habitual PA and Irisin concentration in healthy controls using a standardized questionnaire with the frequency intensity time index as outcome parameter \[[@pone.0189254.ref041]\]. However, we decided to assess the habitual PA level by using the long-form of the IPAQ, since valid and reliable PA data from 18 to 65 year old adults can be collected using this instrument \[[@pone.0189254.ref042]\]. Furthermore, we separated our study group according to sex to reduce sex specific influences. In order to determine the level of short-term PA, we used an accelerometer and also could not find any association between the short-term PA level and the resting Irisin concentration. In contrast, moderate and high intensity ambulatory activity levels were significantly positively associated with Irisin concentrations in a study population consisting of sedentary lean (healthy), obese, prediabetes, and Type 2 diabetes men \[[@pone.0189254.ref030]\]. Unfortunately, the authors did not exclusively focus on the sedentary (healthy) lean subjects in their multiple linear regression analysis. That makes it difficult to compare the results to ours, since our study focused on data of healthy participants. Subjects with diabetes type-2 for example seem to have lower baseline Irisin blood concentrations \[[@pone.0189254.ref030], [@pone.0189254.ref043], [@pone.0189254.ref044]\]. However, the different time frame of wearing the accelerometer should also be considered, as the KarMeN subjects had to wear the accelerometer for a period of seven continuous days compared to three days in the other study. To our knowledge there is no suggestion for an optimal time frame of wearing an accelerometer. Nevertheless, in order to get valid data, a seven day period including a weekday and a weekend has been suggested \[[@pone.0189254.ref045]\].

In our study we focused on the association between the regular PA or PF status and resting Irisin concentration in healthy humans without conducting any intervention. Results from exercise interventions \[[@pone.0189254.ref022], [@pone.0189254.ref024], [@pone.0189254.ref029], [@pone.0189254.ref030], [@pone.0189254.ref032]--[@pone.0189254.ref036], [@pone.0189254.ref046], [@pone.0189254.ref047]\] are therefore not comparable to ours.

As we expected, the sex differences for all body composition parameters and 4 of 6 PA parameters were statistically significant, confirming the necessity of separated calculations for further statistical analysis and moreover for the accuracy of data. Focusing on the differences in resting Irisin blood concentration, no sex differences were found in our study. Consistent with our results, other studies also did not find a sex difference in healthy subjects \[[@pone.0189254.ref031]\] or healthy controls \[[@pone.0189254.ref048]\], while one study showed lower Irisin concentrations in males after adjusting for LBM \[[@pone.0189254.ref020]\].

Conclusion {#sec017}
==========

We performed our study with a large population number of 300 participants and applied three different PA assessment instruments (IPAQ, Accelerometer, and cardiopulmonary exercise testing with additional implementation of lactate test) under strictly controlled conditions using standardized protocols. Thus we were able to investigate the influence of short-term PA, habitual PA, and PF status on resting Irisin serum concentration. Our data clearly show that none of the PA parameters representing short-term PA, habitual PA, as well as PF are associated with resting Irisin serum concentrations in healthy humans. Therefore we assume that if PA related effects are partially induced by myokines, permanently increased Irisin serum concentrations may not be necessary to induce health-related exercise effects. Of course, further research will have to be done to get a better understanding of the association between the resting Irisin concentration and the PA or PF status.
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